2b ar (Biorbyt)
Structured Review

2b Ar, supplied by Biorbyt, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/2b ar/product/Biorbyt
Average 93 stars, based on 2 article reviews
Images
1) Product Images from "Adenosine A 2B Receptor Antagonism Interferes with TGF-β Cellular Signaling Through SMAD2/-3 and p65-Nf-κB in Podocytes and Protects from Phenotypical Transformation in Experimental Diabetic Glomerulopathy"
Article Title: Adenosine A 2B Receptor Antagonism Interferes with TGF-β Cellular Signaling Through SMAD2/-3 and p65-Nf-κB in Podocytes and Protects from Phenotypical Transformation in Experimental Diabetic Glomerulopathy
Journal: Cells
doi: 10.3390/cells14120890
Figure Legend Snippet: Evaluation of the effect of A 2B AR antagonism on renal alterations in experimental DN. ( A ) The experimental design consisted of inducing diabetes in rats through the administration of streptozotocin, with control rats receiving citrate buffer. Treatment with the A 2B AR antagonist MRS1754 (0.5 mg/kg every 48 h) was initiated at week 4 post-diabetes induction. After 8 weeks of treatment, the renal functional and histological alterations were evaluated. The graphs depict the protein-to-creatinine ratio in the urine ( B ), the serum angiotensin 1–8 (Ang II) levels ( C ), and glucosuria ( D ) in the experimental groups. Means ± SD of the samples from 6 animals in each experimental condition are shown. *, p < 0.05 vs. control; #, p < 0.05 vs. diabetes.
Techniques Used: Control, Functional Assay
Figure Legend Snippet: Immunohistochemical analysis of glomerular alterations in diabetic rats. ( A ) The panels show representative immunofluorescent images of the detection of A 2B AR, α-SMA, ZO-1, nephrin, and Snail in renal tissue from control rats, diabetic nephropathy (DN) rats, and diabetic rats treated with the A 2B AR antagonist MRS1754 (DN + MRS1754). The images emphasize changes in the levels of these proteins within the glomerulus. Nuclear staining with DAPI is in blue. The bar indicates 50 µm. ( B ) The graphs correspond to the means ± SD of relative fluorescent units (RFUs) of a quantitative analysis of A 2B AR, α-SMA, ZO-1, nephrin, and Snail in glomeruli from the control (white bar), diabetic (black bar), and MRS1754-treated diabetic (grey bar) rat groups. The means in the control group were normalized to 1. Images of 12 glomeruli from 2 control, 4 diabetic, and 4 treated diabetic rats were analyzed. *, p < 0.05 vs. control; #, p < 0.05 vs. diabetes.
Techniques Used: Immunohistochemical staining, Control, Staining
Figure Legend Snippet: A 2B AR antagonism prevents the loss of podocyte epithelial markers in diabetic glomerulopathy. ( A ) Representative Western blot analysis showing the levels of epithelial ZO-1 and nephrin, as well as mesenchymal α-SMA and Snail, in purified glomeruli from the different rat groups. ( B ) The graphs represent the means and SD of the levels of epithelial and mesenchymal markers relative to β-actin. The means in the control group were normalized to 1. ( C ) Representative Western blot analysis of the Snail distribution in cell fractions purified from the kidneys of experimental rat groups. ( D ) The graph represents the ratio of the Snail subcellular distribution. The mean in the control was normalized to 1. The number of animals analyzed in each experimental group was 5 in ( B ) and 2 in ( D ). *, p < 0.05 vs. control; #, p < 0.05 vs. DN; &, p < 0.05 vs. control.
Techniques Used: Western Blot, Purification, Control
Figure Legend Snippet: A 2B AR antagonism attenuates inflammatory mediators in diabetic rats. ( A ) The graphs depict the levels of the chemokines MCP-1 and CCL3 released from glomeruli and the urinary TGF-β levels in the rat experimental groups. n = 6 samples per duplicate. *, p < 0.05 vs. control; #, p < 0.05 vs. DN; &, p < 0.05 vs. control. ( B ) The heat map highlights changes in the transcript levels of selected inflammation-related genes in the experimental rat groups. The table shows values related to a decrease in the transcripts in the DN + MRS1754 group vs. the DN group.
Techniques Used: Control
Figure Legend Snippet: The antagonism of A 2B AR blocks TGF-β/SMAD3 signaling in podocytes. Differentiated podocytes were incubated in medium containing 25 mM D-glucose (HG) and treated with 10 ng/mL TGF-β and 50 nM MRS1754. ( A ) Upper panel shows the detection of activated phospho-SMAD2/-3 following 0.5 h of treatments in total protein extracts from three independent experiments through Western blot. Lower panel is detection of β-actin as loading control; n = 3. ( B ) Podocytes were treated as above for 48 h, refreshing TGF-β and MRS1754 at 24 h, and harvested for a ChIP-qPCR analysis. The graphs depict normalized means and the SEM occupancy of SMAD3 to the collagen type IA2 and fibronectin promoters; n = 5. *, p < 0.05 vs. HG; #, p < 0.05 vs. TGF-β. ( C ) The graphs show normalized means and the SEM enrichment of H3K9ac at SMAD3 target promoters; n = 5. *, p < 0.05 vs. HG; #, p < 0.05 vs. TGF-β.
Techniques Used: Incubation, Western Blot, Control, ChIP-qPCR

